Evaluating the Effectiveness of CRISPR-Cas9 Technology in Veterinary Medicine for Genetic Disease Treatment in Companion Animals

Abstract

The emergence of CRISPR-Cas9 genome editing technology has opened new avenues for the treatment of inherited genetic diseases in veterinary medicine. This study experimentally evaluated the effectiveness, safety, and clinical relevance of CRISPR-Cas9–based therapeutic interventions in companion animals. A mixed-method approach integrating molecular, clinical, and longitudinal analyses was employed to assess gene-editing efficiency, off-target effects, tissue-specific performance, immune responses, and therapeutic outcomes. Quantitative results demonstrated consistently high editing efficiencies and stable genetic correction across follow-up periods, accompanied by significant reductions in disease-associated biomarkers and marked clinical improvement. Comparative analyses revealed superior survival and recovery outcomes in CRISPR-treated animals relative to conventional therapies. Off-target mutation frequencies were minimal, and immunological evaluations indicated favorable host tolerance. Visual analyses using multiple graphical models further supported the robustness and reproducibility of the findings. The results confirm that CRISPR-Cas9 enables precise, durable, and clinically meaningful genetic correction in companion animals, positioning it as a promising alternative to traditional veterinary treatments. This study provides comprehensive experimental evidence supporting the translational potential of CRISPR-Cas9 technology and highlights its role as a next-generation therapeutic strategy for genetic disease management in veterinary medicine.